Sign in

Already have access? Choose your edition

Sign-in is edition-specific. New here? Start with the free brief instead of jumping straight into a trial.

Each edition has its own app, pricing, and coverage page. Use sign-in if you already have access; otherwise pick an edition and get the free daily + weekly brief first.

AI

Daily briefings on AI labs, policy, tooling, and community shifts.

Best for
  • Model releases + evals
  • Policy and safety narratives
  • Tooling and platform shifts
Flagship sampleUnlocked today
Recent innovations around Claude Code significantly improve multi-session management, remote control, and personal agent deployment.

Crypto

Daily briefings on markets, protocols, narratives, and risk events.

Best for
  • Market structure + regulation
  • Security and exploit narratives
  • Protocol + dev ecosystem
Flagship sampleUnlocked today
Resolv USR stablecoin loses its peg after a $100K exploit minted millions of unbacked tokens, causing sharp devaluation.

CYBERSECURITY

Daily briefings on vulnerabilities, incidents, and threat intel.

Best for
  • Vulns and advisories
  • Incidents + exploit narratives
  • Vendor and community disclosures
Flagship sampleUnlocked today
The US Cybersecurity and Infrastructure Security Agency (CISA) has confirmed active exploitation of a critical remote code execution vulnerability in Microso...

ENERGY

Daily briefings on the energy transition: policy, grid, storage, and markets.

Best for
  • Grid + reliability narratives
  • Policy + first-party data
  • Storage + transition supply chain
Flagship sampleUnlocked today
Israeli strikes on Iran's South Pars gas field, the world's largest, have triggered Iranian retaliatory attacks on Qatar's Ras Laffan LNG hub, wiping out 17%...

BIOTECH

Daily briefings on clinical, regulatory, and R&D updates from public sources.

Best for
  • Clinical + regulatory narratives
  • Research + preprints
  • Funding + market updates
Flagship sampleUnlocked today
Novo Nordisk has secured FDA approval for a higher dose of its obesity drug Wegovy, benefiting from a rare priority review voucher that accelerated clearance...